Reports from the working group
(2022 - 2023)
Lecture Prize of the German Society for Senology e. V.
June 2023
At the 42nd Annual Meeting of the German Society for Senology in Munich, Prof. Dr. Anja K. Wege received a lecture award for her scientific work:
"Noeadjuvnant irradiation and immune checkpoint targeting - a promising approach for breast cancer treatment evaluated in humanized tumor mice. (HTM)"
Lecture Prize of the German Society for Senology e. V.
June 2023
At the 42nd Annual Meeting of the German Society for Senology in Munich, Veruschka Albert received a lecture award for her scientific work:
"Influence of the HER3 and HER4 receptor on the therapy of luminal breast cancer"
Receive a research grant
June 2023
Dr. Christina Bruss has successfully received a research grant as part of the "Breast Cancer" funding program offered by Gilead Sciences GmbH. Title of the funded project:
"Immune checkpoint profiling of T lymphocytes – multiple checkpoints and their potential relevance in immunotherapy in breast cancer"
Lecture Award of the German Society for Senology
July 2022
At the 41st Annual Meeting of the German Society for Senology, Prof. Dr. Anja K. Wege received a lecture award for her scientific work:
"Overexpression of CX3CL1 leads to increased tumor growth but also increased response to treatment with trastuzumab in humanized tumor mice (HTM)."
Lecture Award of the German Society for Senology
July 2022
At the 41st Annual Meeting of the German Society for Senology, Prof. Dr. Gero Brockhoff received a lecture award for his scientific work:
"MDM2 gene amplification is associated with progression and metastasis of luminal breast cancer in the humanized tumor mouse model (hPDX), as well as with an unfavorable clinical course of the disease."
Received GBM Master Prize
September 2022
The Society for Biochemistry and Molecular Biology (GMB e. V.) awards a GBM Master Prize to Veruschka Albert for her outstanding work entitled:
"Analysis of low dose irradiation effects on breast cancer cells in-vitro and in humanized tumor mice (HTM)"